Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells

L. C. J. te Boome, C. Mansilla, L. E. van der Wagen, C. A. Lindemans, E. J. Petersen, E. Spierings, K. A. Thus, K. Westinga, M. Plantinga, M. Bierings, A. E. C. Broers, M. L. H. Cuijpers, G. W. van Imhoff, J. J. Janssen, C. Huisman, S. Zeerleder, G. Huls, J. J. Boelens, N. M. Wulffraat, I. C. M. Slaper-CortenbachJ. Kuball*

*Corresponding author voor dit werk

    OnderzoeksoutputAcademicpeer review

    59 Citaten (Scopus)

    Samenvatting

    We performed a prospective phase II study to evaluate clinical safety and outcome in 48 patients with steroid-refractory grade II-IV acute graft-versus-host disease (aGVHD) treated with mesenchymal stromal cells (MSCs). Clinical outcomes were correlated to comprehensive analyses of soluble and cellular biomarkers. Complete resolution (CR) of aGVHD at day 28 (CR-28) occurred in 12 (25%) patients, CR lasting 41 month (CR-B) occurred in 24 (50%) patients. One-year overall survival was significantly improved in CR-28 (75 versus 33%, P = 0.020) and CR-B (79 versus 8%, P

    Originele taal-2English
    Pagina's (van-tot)1839-1846
    Aantal pagina's8
    TijdschriftLeukemia
    Volume29
    Nummer van het tijdschrift9
    DOI's
    StatusPublished - sep.-2015

    Vingerafdruk

    Duik in de onderzoeksthema's van 'Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit